Humanin neuroprotection research dosing

Humanin half-life is on the order of hours. Research dosing typically uses daily or twice-daily administration for sustained effect.

Note: the 2024 glioblastoma data is a real caveat for any extension to cancer-relevant populations. The anti-apoptotic mechanism cuts both ways.